Among 1866 women of childbearing age enrolled in the DART trial of antiretroviral therapy monitoring strategies in Uganda and Zimbabwe, 221 pregnancies were reported (in 198 women) after a median of 2.8 years of follow-up. Almost all women continued taking their drugs during pregnancy and delivery. Pregnancy rates increased over time; rates of foetal loss varied between sites. Among the 164 pregnancies which had reached a known outcome at the time of writing, 55% resulted in a live birth. Congenital abnormality rates appeared similar to those in other studies. No infant had been diagnosed as infected at the time of writing, although some women chose to breastfeed; follow-up of infants was ongoing.
14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, USA, 25-28 February 2007: Abstract 746.
Pregnancy and pregnancy outcome among women in the DART trial.